Emergent BioSolutions (Winnipeg)
Manitoba · Canada
Key Differentiator
STRATEGIC CANADIAN ASSET — One of only 2 global manufacturing sites Emergent retained during restructuring (divested Bayview & Camden Baltimore sites)
Core Services
Market Intelligence
STRATEGIC CANADIAN ASSET — One of only 2 global manufacturing sites Emergent retained during restructuring (divested Bayview & Camden Baltimore sites). FDA sBLA approved Dec 2025 for raxibacumab mAb manufacturing. New PHAC/DND contracts (Feb 2026) for Canada biological threat preparedness. Providence Therapeutics mRNA vaccine partnership ($90M baseline). Critical for Canadian pandemic preparedness. Unique dual US/Canada regulatory compliance.
Similar Companies
AGC Biologics
Bothell, WA (US HQ); Boulder, CO; Longmont, CO ·
Proprietary CHEF1® expression system
ARSI Canada Inc.
Mississauga, ON (Unit 16, 6800 Kitimat Rd) · Custom synthesis, analytical development, drug development
Mississauga CRO
Actylis (Montreal Operations)
Quebec ·
Global API and excipient supplier with Canadian manufacturing
Ajinomoto Bio-Pharma Services
San Diego, CA; Oss, Netherlands ·
Proprietary AJICAP™ site-specific ADC bioconjugation technology
Need help finding the right outsourcing partner?
Try AI NavigatorCompany information is sourced from publicly available data and may not be current. PharmoniQ does not endorse any company listed. Contact companies directly for the most up-to-date information.